3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
10
Leukemia, Lymphocytic, Chronic, B-Cell
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Monocytic, Acute
4
Leukemia, Megakaryoblastic, Acute
4
Leukemia, Erythroblastic, Acute
4
Leukemia
4
Congenital Abnormalities
4
Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Lymphoma
2
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Hematologic Neoplasms
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Venous Thromboembolism
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sezary Syndrome
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Interventions
Cytarabine
4
Azacitidine
3
sargramostim
2
cc-486
2
Monatide (IMS 3015)
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Decitabine
2
venetoclax
1
thymoglobulin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
fludarabine phosphate
1
fludarabine
1
eltrombopag
1
Whole-Body Irradiation
1
Tacrolimus
1
Sulindac
1
Rituximab
1
Observation
1
Mycophenolic Acid
1
Methotrexate
1
Melphalan
1
Cyclophosphamide
1
Clofarabine
1
Busulfan
1
Bone Marrow Transplantation
1
Blood Specimen Collection
1
Antilymphocyte Serum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Observation
×
Other hematologic neoplasm
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled